REVB vs. GRTX, ERNA, CMMB, VAXX, UPC, ABVC, NCNA, OGEN, ATHE, and ADXN
Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Galera Therapeutics (GRTX), Eterna Therapeutics (ERNA), Chemomab Therapeutics (CMMB), Vaxxinity (VAXX), Universe Pharmaceuticals (UPC), ABVC BioPharma (ABVC), NuCana (NCNA), Oragenics (OGEN), Alterity Therapeutics (ATHE), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical preparations" industry.
Galera Therapeutics (NASDAQ:GRTX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Galera Therapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Galera Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Revelation Biosciences' return on equity of 0.00% beat Galera Therapeutics' return on equity.
In the previous week, Galera Therapeutics and Galera Therapeutics both had 2 articles in the media. Revelation Biosciences' average media sentiment score of 1.43 beat Galera Therapeutics' score of 0.43 indicating that Galera Therapeutics is being referred to more favorably in the media.
Galera Therapeutics received 20 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.
50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 6.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Galera Therapeutics beats Revelation Biosciences on 7 of the 11 factors compared between the two stocks.
Get Revelation Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revelation Biosciences Competitors List
Related Companies and Tools
